Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857889 | 1.00 | BTK (0.32) | BTKDGAT1KDM1A | |
| SCHEMBL12987712 | 1.00 | BTK (0.32) | BTKDGAT1KDM1A | |
| SCHEMBL4197528 | 0.95 | BTK (0.31) | BTKDGAT1KDM1A | |
| SCHEMBL2557566 | 0.95 | BTK (0.31) | BTKDGAT1KDM1A | |
| SCHEMBL4206000 | 0.95 | BTK (0.31) | BTKDGAT1KDM1A | |
| SCHEMBL12987233 | 0.95 | BTK (0.31) | BTKDGAT1KDM1A | |
| SCHEMBL2561559 | 0.95 | BTK (0.31) | BTKDGAT1KDM1A | |
| SCHEMBL27508813 | 0.90 | DGAT1 (0.33) | BTKDGAT1KDM1A | |
| SCHEMBL27905691 | 0.86 | DGAT1 (0.33) | BTKDGAT1KDM1A | |
| SCHEMBL4831767 | 0.83 | DGAT1 (0.31) | BTKDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819999-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Novartis AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| CN-101723937-B | Imidazol-4-one and imidazole-4-thione compounds | NAT HEALTH RESEARCH INSTITUTES | 2014-11-19 | — | — | CN | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| CN-102906095-A | Pyrrolopyrazine derivatives as SYK and JAK inhibitors | HOFFMANN LA ROCHE | 2013-01-30 | — | — | CN | disclosed |
| CN-102803204-A | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD COLORADO INC | 2012-11-28 | — | — | CN | disclosed |
| CN-102076662-A | Alpha-mercapto-amides | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| CN-101723937-A | imidazol-4-one and imidazole-4-thione compounds | NAT HEALTH RESEARCH INSTITUTES | 2010-06-09 | — | — | CN | disclosed |
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1921066-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| CN-101155803-A | Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate | INKE SA (ES) | 2008-04-02 | — | — | CN | disclosed |
| CN-101044116-A | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | CN | disclosed |
| CN-1950369-A | Novel benzothiazoles and the use thereof as medicaments | AVENTIS PHARMA SA (FR) | 2007-04-18 | — | — | CN | disclosed |
| CN-1902191-A | Amidopyrazole derivative | DAIICHI SEIYAKU CO (JP) | 2007-01-24 | — | — | CN | disclosed |
| CN-1317968-A | 2-bustituted-1-piperidyl benzimidazole compounds as or/1-receptor agonists | PFIZER PHARMA (US) | 2001-10-17 | — | — | CN | disclosed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156646-A1 | PYRIDYLPHENOL COMPOUND AND USE THEREOF | GNRHR, PGR, MC1R | BTK 4801/4885DGAT1 4883/4885KDM1A 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.